China’s Hua Medicine plans $400 million Hong Kong IPO, led by Goldman – sources

Shanghai-based Hua, a diabetes-focused drug developer, had considered both locations but selected Hong Kong because of the city’s proposed new listings regime, which Hong Kong Exchanges and Clearing expects to have in place within a couple of months …
( read original story …)


Related Post